ELMWOOD PARK, N.J.,
Sept. 2, 2020 /PRNewswire/
-- BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ:OPK), today began testing New
York City principals, teachers and other staff for COVID-19,
across the five boroughs, in preparation for a safer back-to-school
environment.
Through a strategic collaboration with BioReference,
New York City, the Department of
Health and New York City Health and Hospital Corporation
(NYC Health + Hospitals) will
collect specimens from principals, teachers and staff members
across eight locations. BioReference will then perform COVID-19 PCR
tests for the principals, teachers and other school staff at its
Elmwood Park, New Jersey
laboratory facility. The hours of operation for collection of
specimens will be 8:00 a.m. to 8:00 p.m.
ET, Monday through Sunday, beginning today and concluding
Monday, September 7. Registration and
appointment selection is required. To register for collection of a
specimen for a COVID-19 test, visit:
https://appointments.bioreference.com/nycschools.
"As NYC schools prepare for the
upcoming year, COVID-19 testing will play a pivotal role in
supporting a safer overall classroom environment for educators,
students and their families," said Jon R. Cohen, M.D.,
Executive Chairman of BioReference Laboratories. "The systematic
measures put in place by New York
City reaffirm the dedication to safety and education in
New York City."
About BioReference Laboratories, Inc.
BioReference
provides comprehensive testing to physicians, clinics, hospitals,
employers, government units, correctional institutions and medical
groups. BioReference has been working expeditiously to develop
and offer test services that will yield high quality and accurate
results, including a molecular test for helping with COVID-19
diagnosis and a serology test to help indicate possible COVID-19
exposure. The company is in network with the five largest health
plans in the United States,
operates a network of 11 laboratory locations, and is backed by a
medical staff of more than 120 M.D., Ph.D. and other
professional level clinicians and scientists. With a leading
position in the areas of genetics, women's health, maternal fetal
medicine, oncology and urology, BioReference and its specialty
laboratories, GenPath and GeneDx, are advancing the course of
modern medicine. For more information,
visit www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational
biopharmaceutical and diagnostics company that seeks to establish
industry-leading positions in large, rapidly growing markets by
leveraging its discovery, development, and commercialization
expertise and novel and proprietary technologies. For more
information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," as that term is defined under the Private Securities
Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
the role COVID-19 testing will play in supporting a safer classroom
environment, the accuracy and availability of the test and the role
and value of the information provided and its impact on decisions
relative to the safety of educators, students and their families,
as well as other non-historical statements about our expectations,
beliefs or intentions regarding our business, technologies and
products, financial condition, strategies or prospects. Many
factors could cause our actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements. These factors include those described
in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to
be filed with the Securities and Exchange Commission and in its
other filings with the Securities and Exchange Commission. In
addition, forward-looking statements may also be adversely affected
by general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/opko-healths-bioreference-laboratories-announces-new-york-city-schools-covid-19-testing-program-301122624.html
SOURCE BioReference Laboratories, Inc